Axogen (Nasdaq:AXGN) today announced it has launched its Avive+ Soft Tissue Matrix.

Philips, a global leader in health technology, has announced the first implant of the Duo Venous Stent System, an implantable medical device indicated to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI), following premarket approval (PMA) from the U.S. Food and Drug Administration (FDA).

Globus Medical has won FDA clearance for its new ExcelsiusFlex orthopedics robot stereotaxic surgery in knee procedures and an expanded indication for its ExcelsiusHub system.

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) — Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation (EU MDR) certificate and CE Mark certification for four of its products.

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.

DALLAS, June 19, 2024 /PRNewswire/ — 4WEB Medical, an orthopedic implant company focused on developing innovative implants that utilize its proprietary Truss Implant Technology™, announced the initial launch of the newest addition to the company’s portfolio, the Cervical Spine Truss System Integrated Plating Solution (CSTS-IPS). The first procedures were performed by Kris Parchuri, DO, orthopedic spine surgeon at Spine & Orthopedic Specialists in Tulsa, OK and Jason Alder, MD, Director of Spinal Surgery at Baylor Scott & White Medical Center in Frisco, TX.

The designation recognises the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease.

SHANGHAI, June 17, 2024 /PRNewswire/ — MicroPort® CardioFlow Medtech Corporation (CardioFlow) (Stock Code: 02160.HK) recently announced that its self-developed second-generation transcatheter aortic valve implantation (TAVI) device, the VitaFlow LibertyTM Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow LibertyTM), has received EU CE-MDR certification. This certification highlights VitaFlow LibertyTM as a pioneering TAVI solution, that sets a new benchmark in transcatheter heart valve treatments.